Science Corporation began the European commercial launch of PRIMA, a subretinal photovoltaic implant that restored functional central vision in patients with geographic atrophy from age-related macular degeneration. CE-marked across 30 countries, it's the first BCI cleared for form-vision restoration; 80% of trial patients could read letters and words. First German procedures could come in September.
Science Corporation — Science began PRIMA's European commercial launch under a CE mark valid across 30 countries — the first BCI cleared anywhere for form-vision restoration. Its subretinal photovoltaic implant plus camera glasses restored functional central vision in geographic-atrophy (dry-AMD) patients; 80% read letters, numbers and words in the NEJM-published trial. First German procedures could come in September.
Science Corporation — Science closed an oversubscribed $230M Series C (total ~$490M) to commercialize PRIMA — a retinal BCI that restored form vision in dry-AMD patients (NEJM-published). A European launch later this year would make it the first BCI vision product on the market.
